Citius Oncology Announces Closing of $9.0 Million Public Offering

Citius Oncology Announces Closing of $9.0 Million Public Offering

CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of…

Citius Oncology Secures $9M Through Share Offering: LYMPHIR Drug Launch Gets Funding Boost

$9M offering at $1.32/share with warrants to fund LYMPHIR commercialization. Details on share count, warrant terms, and use of proceeds. See full terms.